Moreover, we unambiguously demonstrated that ebselen oxide in combination with lapatinib or trastuzumab exerts an additive effect on the inhibition of HER2 activation and/or proliferation of HER2‐positive cancer cells. Here, ERBB2 is linked to cancer.